In short
This article discusses a clinical trial investigating the use of agents for dermatitis (excluding corticosteroids) in children and teenagers with moderate to severe atopic dermatitis, also known as eczema. The study focuses on a drug called lebrikizumab, which is being tested in combination with topical corticosteroids to assess its efficacy and safety in treating this skin condition.
At a glance
- Study Type
- Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study
- Drug Studied
- Lebrikizumab (LY3650150)
- Condition
- Moderate to Severe Atopic Dermatitis
- Age Group
- 6 months to <18 years
- Treatment Combination
- Lebrikizumab with Topical Corticosteroids
- Primary Endpoints
- 1. IGA score 0 or 1 with ≥2 point reduction; 2. EASI-75 (≥75% reduction in EASI score)
- Maximum Treatment Duration
- 18 weeks
- Drug Category
- Agents for Dermatitis, Excluding Corticosteroids
- Administration Route
- Topical
What is this Treatment?
A new treatment for atopic dermatitis, also known as eczema, is being studied for children and teenagers. This treatment falls under the category of "Agents for Dermatitis, Excluding Corticosteroids." The specific drug being tested is called lebrikizumab (LY3650150).
Atopic dermatitis is a chronic skin condition that causes itchy, inflamed skin. It's common in children but can affect people of all ages. This new treatment offers an alternative to corticosteroids, which are commonly used but can have side effects with long-term use.
How Does it Work?
While the exact mechanism isn't specified in the trial information, agents for dermatitis that exclude corticosteroids often work by targeting specific parts of the immune system that are involved in causing inflammation in the skin. Lebrikizumab, the drug being studied, likely works in this way to reduce the symptoms of atopic dermatitis.
Who Can Use This Treatment?
This treatment is being studied for use in children and teenagers with moderate-to-severe atopic dermatitis. The study includes participants from 6 months to less than 18 years of age.
Eligibility Criteria
To be eligible for the study, participants must meet several criteria:
- Have had atopic dermatitis for at least 6 months (if younger than 6 years old) or 1 year (if older than 6 years)
- Be between 6 months and 6 years old and weigh over 6 kilograms, or be between 12 and 18 years old and weigh less than 40 kilograms
- Have a parent or legal guardian who can provide consent and follow study guidelines
Who Should Not Use This Treatment?
Some people may not be eligible for this treatment. Exclusion criteria include:
- Recent participation in a similar study or use of certain forbidden treatments
- Pregnancy or breastfeeding
- Previous allergic reactions to the study drug or related substances
- Severe or current infections requiring strong antibiotics
- Certain medical conditions that could affect safety
- Drug or alcohol addiction
How Effective is the Treatment?
The effectiveness of this treatment is being measured in two main ways:
- The percentage of participants who achieve an Investigator Global Assessment (IGA) score of 0 or 1 and a reduction of at least 2 points from their baseline score. An IGA score is a way for doctors to measure the severity of atopic dermatitis.
- The percentage of participants who achieve at least a 75% reduction in their Eczema Area and Severity Index (EASI) score. The EASI score is another tool used to measure the extent and severity of atopic dermatitis.
These measurements will help determine how well the treatment works in reducing the symptoms and severity of atopic dermatitis in children and teenagers.
How is the Treatment Administered?
The treatment is administered topically, which means it's applied directly to the skin. The study mentions that it's used in combination with topical corticosteroids (TCS), suggesting that patients may use both this new treatment and traditional corticosteroid creams or ointments as part of their treatment plan.
The maximum daily dose is 1 unit (the specific unit is not specified), and the maximum total dose over the course of treatment is 126 units. The maximum treatment period is 18 weeks.